Journal Club - Do We Still Need a DAT on Every Newborn at Risk of Hemolytic Disease?

Summary

Ben and Daphna review a Pediatrics study of over 1,300 infants questioning routine direct antiglobulin testing (DAT) in low-risk newborns with ABO or RhD incompatibility, including whether transcutaneous bilirubin alone predicts the need for phototherapy. They discuss the implications for units testing every at-risk baby, how to distinguish passive anti-D from true alloimmunisation, and a more targeted approach to bilirubin screening.